For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Scope of the Report:
In the last several years, global market of alzheimer's disease drug change huge.
The classification of alzheimer's disease drug includes Memantine, Donepezil, Rivastigmine and Others, and the proportion of Memantine in 2016 is about 49.28%. The market for Donepezil, is decreast quickly in past five years.
Alzheimer's disease drug are widely used for Early to Moderate, Moderate to Severe stage treatment. The most proportion of alzheimer's disease drug used to Moderate to Severe, and the market share in 2016 is 55.82%.
The worldwide market for Alzheimer's Disease Drug is expected to grow at a CAGR of roughly -11.3% over the next five years, will reach 1580 million US$ in 2024, from 2870 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Alzheimer's Disease Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Allergan
- Eisai
- Novartis
- Daiichi Sankyo
- Merz Pharma
- Pfizer
- Johnson & Johnson
- Lundbeck
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Donepezil
- Memantine
- Rivastigmine
Market Segment by Applications, can be divided into
- Early to Moderate Stages
- Moderate to Severe Stages
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Alzheimer's Disease Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Alzheimer's Disease Drug, with price, sales, revenue and global market share of Alzheimer's Disease Drug in 2017 and 2018.
Chapter 3, the Alzheimer's Disease Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Alzheimer's Disease Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Alzheimer's Disease Drug market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Alzheimer's Disease Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.